Search
FibroGen Ord Shs
KYNBAdd to Watchlist
7.250USD
-0.030-0.41%
Close 09-23 16:00（ET）
29.36MMarket Cap
0.18P/E TTM
FibroGen Ord Shs (KYNB) Stock Price Target & Forecast
Analyst Rating
Based on 4 analysts
Buy
1 Strong Buy
2 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
39.667USD+444.87%
KYNB Analyst Recommendation Trends
In the current month, KYNB has received 2 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. KYNB average Analyst price target in the last month is 39.667.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
0
0
0
0
0
0
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4
3
2
2
2
2
2
2
KYNB Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
7
17
12
1
0
37
Amgen Inc
AMGN
4
12
18
2
1
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Merck & Co Inc
MRK
8
14
10
0
0
32
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, KYNB EPS is projected to reach -3.660 in FY2026Q3, following reported EPS of 2.958 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-3.88
-3.35
-3.18
-3.66
-3.91
Actual
-3.51
-3.76
2.96
--
--
Surprise
+9.53%
-11.93%
+192.93%
--
--
FAQs
What is FibroGen Ord Shs's expected revenue for the next quarter?
FibroGen Ord Shs's expected revenue is 2.05M.
What is FibroGen Ord Shs's price target?
Analysts forecast that FibroGen Ord Shs's price target is USD 39.67, with the highest forecast at USD 43.00 and the lowest forecast at USD 35.00.
How have FibroGen Ord ShsKYNB's recent earnings per share performed?
The market expectation was USD 2.96, while FibroGen Ord ShsKYNB's earnings per share (EPS) for the previous quarter was USD -3.76. EPS for the next quarter is expected at USD -3.66.
What is the analyst rating for FibroGen Ord Shs?
Based on the ratings of FibroGen Ord Shs's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.